14 April 2025 - Organon today announced that Health Canada has approved Nduvra (tapinarof cream), 1%, the first in a novel class of aryl hydrocarbon receptor agonists to be approved in Canada, for the topical treatment of plaque psoriasis in adults.

The approval of Nduvra is based on the results from two randomised, double-blind, multi-centre, vehicle-controlled trials conducted to evaluate the safety and efficacy of tapinarof cream for the treatment of adults with plaque psoriasis (symptoms varying from mild to severe).

Read Organon press release